Introduction {#tca12858-sec-0005}
============

Thyroid cancer is a common malignancy of the endocrine system and occurs more frequently in women than men.[1](#tca12858-bib-0001){ref-type="ref"} Over the past few decades, the incidence of thyroid cancer has increased in different countries, including the United States, United Kingdom, France, Canada, and Australia.[2](#tca12858-bib-0002){ref-type="ref"} In China, the annual incidence appreciably increased by 14.51% in women during 2003--2007.[3](#tca12858-bib-0003){ref-type="ref"} Rahib *et al*. reported that thyroid cancer will become the fourth most common cancer by 2030 in the United States if recent trends are maintained.[4](#tca12858-bib-0004){ref-type="ref"} The burden of thyroid cancer is substantial, thus proper preventive measures and treatment are urgently required.

Among the Chinese population, the features of thyroid cancer differ across various regions. For example, Yang *et al*. showed a gender ratio of 1:3 (1185 men: 3698 women), while Li *et al*. reported 1:3.56.[5](#tca12858-bib-0005){ref-type="ref"}, [6](#tca12858-bib-0006){ref-type="ref"}, [7](#tca12858-bib-0007){ref-type="ref"} Other features, such as pathological distribution and *BRAF* mutations, are diverse. In this study, we investigated thyroid cancer cases in northwest China from August 2015 to June 2018 and provide information from specific areas to predict the burden of thyroid cancer in northwest China.

Methods {#tca12858-sec-0006}
=======

Data collection {#tca12858-sec-0007}
---------------

Patients newly diagnosed with thyroid carcinoma between August 2015 and June 2018 were enrolled in the study. Clinical characteristics were collected from the thyroid database established by Xijing Hospital. Two independent researchers performed data collation and entry. In cases of disagreement, another researcher was consulted for judgment until a consensus was reached. The study was conducted in accordance with The Code of Ethics of the Declaration of Helsinki and the ethical standards of the ethics committee of Air Force Medical University. We guaranteed that the personal information of the participants was protected.

Pathological diagnostic criteria {#tca12858-sec-0008}
--------------------------------

The pathological outcome was determined by at least two experienced pathologists from the Pathology Department of Xijing Hospital, based on standard definitions set by the World Health Organization (WHO).[8](#tca12858-bib-0008){ref-type="ref"} Thyroid cancer was classified into papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), anaplastic thyroid cancer (ATC), and medullary thyroid cancer (MTC), based on histopathological characteristics.

Statistical analysis {#tca12858-sec-0009}
--------------------

Statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). A Pearson\'s chi‐squared (*χ* ^2^) test was performed to determine the differences in clinicopathological factors between the groups. Continuous outcomes were analyzed using independent *t*‐tests for groups of two and one‐way analysis of variance among groups of three of more. *P* \< 0.05 was considered significant. Multiple logistic regression analysis was applied to identify risk factors for *BRAF* ^V600E^ mutation.

Results {#tca12858-sec-0010}
=======

Patients {#tca12858-sec-0011}
--------

A total of 2490 patients (1884 women: 606 men = 3.1:1) were included in the study. The average age of patients was 43.3 ± 11.19 years (range: 5--80). The patients were all from northwest China, including Shaanxi, Shanxi, Xinjiang, Ningxia, and Gansu. As indicated, 98% (2440/2490) of thyroid cancer patients were identified with PTC, and more than half of these PTC patients (1295/2440) were diagnosed with papillary thyroid microcarcinoma (PTMC). Other histological types, including FTC, ATC, and MTC accounted for 0.8%, 0.04%, and 0.5%, respectively. In regard to *BRAF* ^v600E^ gene expression, 68.6% of participants were detected with the *BRAF* ^v600E^gene and 84.5% of them showed gene mutation. The baseline features of the patients are presented in Table [1](#tca12858-tbl-0001){ref-type="table"}.

###### 

Baseline features (*n* = 2490)

  Index                   N (%)               Index                    N (%)
  ----------------------- ------------------- ------------------------ --------------
  Age                                         Education                
  Average age             43.3 ± 11.19        High school or below     1340 (53.8%)
  Median age              44 (5--80)          College                  1013 (40.7%)
  ≤ 45                    1408 (56.5%)        Postgraduate and above   137 (5.5%)
  \> 45                   1082 (43.5%)        Marriage                 
  Gender                                      Yes                      2267 (91.0%)
  Female                  1884 (75.7%)        No                       223 (9.0%)
  Male                    606 (24.3%)         Pathology                
  Blood type                                  PTC                      1145 (46.0%)
  A                       718 (28.8%)         FTC                      20 (0.8%)
  B                       754 (30.3%)         ATC                      1 (0.04%)
  AB                      382 (15.3%)         MTC                      12 (0.5%)
  O                       636 (25.5%)         PTMC                     1295 (52.0%)
  *BRAF* detection rate   1708 (68.6%)        Others                   17 (0.68%)
  *BRAF* mutation                             Weight (kg)              
  Yes                     1444/1708 (84.5%)   Average                  64.1 ± 11.44
  No                      264/1708 (15.5%)    Range                    16--106

ATC, anaplastic thyroid cancer; FTC, follicular thyroid cancer; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma.

Clinicopathological features of patients of different ages {#tca12858-sec-0012}
----------------------------------------------------------

To investigate the influence of patient age on clinicopathological features, we divided all patients into a children/adolescent group (≤ 20 years old) and adult groups of various age ranges (21--45, 46--59, ≥ 60 years) (Table [2](#tca12858-tbl-0002){ref-type="table"}). Weight (*F* = 10.609, *P* \< 0.001), blood type (*χ* ^2^ = 153.656, *P* \< 0.001), histological type (*χ* ^2^ = 131.724, *P* \< 0.001), lymph node metastasis (*χ* ^2^ = 57.654, *P* \< 0.001), surgical method (*χ* ^2^ = 10.103, *P* = 0.018), and *BRAF* ^V600E^ mutations (*χ* ^2^ = 37.511, *P* \< 0.001) differed among the groups. Using 45 years of age as cutoff value, we found that patients aged ≤ 45 weighed the least (Table [3](#tca12858-tbl-0003){ref-type="table"}). In regard to blood types, differences were observed between patients aged ≤ 45 and \> 45 years (*P* \< 0.001): 65.4% of patients aged ≤ 45 had A or B blood types, while 60.0% of those aged \> 45 years had A or O blood types. Regarding the distribution of histological types, the proportions of patients with PTC and PTMC were 51.1% versus 39.4% in the group aged ≤ 45, and 47.7% versus 57.6% in the group aged \> 45 years, respectively. Similarly, the *BRAF* ^V600E^ gene mutation rate in all patients was 80%, but patients aged \> 45 years had a 7.6% greater mutation rate than the other groups. There were no differences in the distributions of gender, lesions, lymph node metastasis, surgery method, or recurrence rate. After a medium follow‐up duration of 24 months (range: 1--34), the rate of recurrence in thyroid carcinoma patients was ≤ 10%. The lung and bones were common locations for recurrence.

###### 

Characteristics of thyroid cancer patients by age group

  ------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                           \< 21\          21--45\             46--59\           ≥ 60\             *χ* ^2^/*F*   *P*
                                            (*n* = 65)      (*n* = 1343)        (*n* = 905)       (*n* = 177)                     
  ----------------------------------------- --------------- ------------------- ----------------- ----------------- ------------- ----------
  Gender                                                                                                                          

  Male (*n* = 606)                          14 (21.5%)      335 (24.9%)         209 (23.1%)       48 (27.1%)        2.048         0.562

  Female (*n* = 1884)                       51 (78.5%)      1008 (75.1%)        696 (76.9%)       129 (72.9%)                     

  Weight                                    52.17 ± 13.54   63.9 ± 11.71        65.2 ±10.61       63.12 ± 9.89      10.609        \< 0.001

  Blood type                                                                                                                      

  A (*n* = 718)                             22 (33.8%)      401 (29.9%)         244 (27.0%)       51 (28.8%)        153.656       \< 0.001

  B (*n* = 754)                             12 (18.5%)      487 (36.3%)         195 (21.5%)       60 (33.9%)                      

  AB (*n* = 382)                            17 (26.2%)      198 (14.7%)         122 (13.5%)       45 (25.4%)                      

  O (*n* = 636)                             14 (21.5%)      257 (19.1%)         344 (38.0%)       21 (11.9%)                      

  Lesion                                                                                                                          

  Unilateral (*n* = 1473)                   37 (56.9%)      803 (59.8%)         540 (59.7%)       93 (52.5%)        3.661         0.3

  Bilateral (*n* = 1017)                    28 (43.1%)      540 (40.2%)         365 (40.3%)       84 (47.5%)                      

  Histological type                                                                                                               

  PTC (*n* = 1145)                          48 (73.8%)      671 (50.0%)         338 (37.3%)       88 (49.7%)        131.724       \< 0.001

  PTMC (*n* = 1295)                         11 (16.9%)      661 (49.2%)         544 (60.1%)       79 (44.6%)                      

  FTC (*n* = 20)                            5 (7.7%)        6 (0.4%)            6 (0.7%)          3 (1.7%)                        

  MTC (*n* = 12)                            1 (1.5%)        4 (0.3%)            5 (0.6%)          2 (1.1%)                        

  Others (*n* = 18)                         0               1 (0.1%)            12 (13.3%)        5 (2.8%)                        

  LN metastasis                                                                                                                   

  Yes (*n* = 1174)                          59 (90.8%)      605 (45.0%)         441 (48.7%)       69 (39.0%)        57.654        \< 0.001

  No (*n* = 1316)                           6 (9.2%)        738 (55.0%)         464 (51.3%)       108 (61.0%)                     

  Surgery                                                                                                                         

  Total thyroidectomy (*n* = 2087)          54 (83.1%)      1143 (85.1%)        733 (81.0%)       157 (88.7%)       10.103        0.018

  Near‐total thyroidectomy (*n* = 403)      11 (16.9%)      200 (14.9%)         172 (19.0%)       20 (11.3%)                      

  *BRAF* detection rate (*n* = 1708/2490)   30/65 (46.2%)   947/1343 (70.5%)    614/905 (67.8%)   117/177 (66.1%)   18.237        \< 0.001

  *BRAF* mutation                                                                                                                 

  Yes (*n* = 1444)                          16/30 (53.3%)   778/947 (82.2%)     544/614 (88.6%)   106/117 (90.6%)   37.511        \< 0.001

  No (*n* = 264)                            14/30 (46.7%)   169/957 (17.7%)     70/617 (11.3%)    11/117 (9.4%)                   

  Follow‐up rate                            56/65 (86.2%)   1200/1343 (89.4%)   759/905 (83.9%)   104/177 (58.8%)   104.978       \< 0.001

  Recurrence                                                                                                                      

  Yes                                       10 (15.4%)      123 (9.2%)          78 (8.6%)         11 (6.2%)         5.135         0.162

  No                                        55 (84.6%)      1220 (90.8%)        827 (91.4%)       166 (93.8%)                     
  ------------------------------------------------------------------------------------------------------------------------------------------

FTC, follicular thyroid cancer; LN, lymph node; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma.

###### 

Characteristics of thyroid cancer patients aged ≤ 45 and \> 45 years

  ---------------------------------------------------------------------------------------------------------
  Characteristics                           ≤ 45\               \> 45\             *χ* ^2^/*F*   *P*
                                            (*n* = 1408)        (*n* = 1082)                     
  ----------------------------------------- ------------------- ------------------ ------------- ----------
  Gender                                                                                         

  Male (*n* = 606)                          349 (24.8%)         257 (23.8%)        0.356         0.551

  Female (*n* = 1884)                       1059 (75.2%)        825 (76.2%)                      

  Weight                                    63.36 ± 12.63       64.86 ± 10.25      6.855         0.009

  Blood type                                                                                     

  A (*n* = 718)                             423 (30.0%)         295 (27.3%)        80.401        \< 0.001

  B (*n* = 754)                             499 (35.4%)         255 (23.6%)                      

  AB (*n* = 382)                            215 (15.3%)         167 (15.4%)                      

  O (*n* = 636)                             271 (19.2%)         365 (33.7%)                      

  Lesion                                                                                         

  Unilateral (*n* = 1473)                   840 (59.7%)         633 (58.5%)        0.339         0.561

  Bilateral (*n* = 1017)                    568 (40.3%)         449 (41.5%)                      

  Histological type                                                                              

  PTC (*n* = 1145)                          719 (51.1%)         426 (39.4%)        49.759        \< 0.001

  PTMC (*n* = 1295)                         672 (47.7%)         623 (57.6%)                      

  FTC (*n* = 20)                            11 (0.8%)           9 (0.8%)                         

  MTC (*n* = 12)                            5 (0.4%)            7 (0.6%)                         

  Others (*n* = 18)                         1 (0.1%)            17 (1.6%)                        

  LN metastasis                                                                                  

  Yes (*n* = 1174)                          664 (47.2%)         510 (47.1%)        0.00          0.99

  No (*n* = 1316)                           744 (52.8%)         572 (52.9%)                      

  Surgery                                                                                        

  Total thyroidectomy (*n* = 2087)          1197 (85.0%)        890 (82.3%)        3.434         0.064

  Near total thyroidectomy (*n* = 403)      211 (15.0%)         192 (17.7%)                      

  *BRAF* detection rate (*n* = 1708/2490)   977/1408 (69.4%)    731/1082 (67.6%)   0.95          0.33

  *BRAF* mutation                                                                                

  Yes (*n* = 1444)                          794/977 (81.3%)     650/731 (88.9%)    18.727        \< 0.001

  No (*n* = 264)                            183/987 (18.5%)     81/734 (11.1%)                   

  Follow‐up rate                            1256/1408 (89.2%)   863/1082 (79.8%)   43.044        \< 0.001

  Recurrence                                                                                     

  Yes                                       133 (9.4%)          89 (8.2%)          1.122         0.289

  No                                        1275 (90.6%)        993 (91.8%)                      
  ---------------------------------------------------------------------------------------------------------

FTC, follicular thyroid cancer; LN, lymph node; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma.

Clinical features of thyroid cancer in children {#tca12858-sec-0013}
-----------------------------------------------

In the 65 pediatric thyroid cancer patients, the ratio of girls to boys was 3.64:1. The distributions of blood type, histological type, and lesions are shown in Table [2](#tca12858-tbl-0002){ref-type="table"}. In contrast to adult patients, younger patients possessed higher lymph node metastasis and lower *BRAF* ^V600E^ mutation rates (Table [2](#tca12858-tbl-0002){ref-type="table"}). In respect to surgical treatment, children with thyroid cancer were treated following the same guidelines as adults. Postoperatively, 83.1% (54/65) of children underwent radioactive iodine (RAI) ablation with iodine‐131 (131I) to detect metastatic disease, treat residual tumors and metastases, and to ablate any remaining normal thyroid tissue. Excluding 9 patients lost to follow‐up, 10 (15.4%) patients developed recurrence, a rate 6.2--9.2% higher than in adult patients. The most common sites of recurrence were the lungs, wall of the chest, and claviculate.

Correlation between histological type and clinical features {#tca12858-sec-0014}
-----------------------------------------------------------

We analyzed the specific pathological features of each histological type, which are summarized in Table [4](#tca12858-tbl-0004){ref-type="table"}. As shown, 59.7% of patients with PTC had unilateral lesions, 42.6% were multifocal, 72.1% had lymph node metastasis, and 84.6% had *BRAF* ^V600E^ mutations. Similarly, in PTMC patients, 58.1% had unilateral lesions, 51.7% were multifocal, 76.0% had lymph node metastasis, and 85.3% had *BRAF* ^V600E^ mutations. However, for other types of thyroid cancer, predominantly FTC, the clinical features were different: 76.0% of patients with PTC had unilateral lesions, 38.0% were multifocal, 24.0% had lymph node metastasis, and 42.1% had *BRAF* ^V600E^ mutations. There were no differences in local recurrence among the thyroid cancer types.

###### 

Correlation between histological type and clinical features

  ------------------------------------------------------------------------------------------------------------
  Characteristics           PTC (*n* = 1145)   PTMC (*n* = 1295)   Other (*n* = 50)   *χ* ^2^/*F*   *P*
  ------------------------- ------------------ ------------------- ------------------ ------------- ----------
  Gender                                                                                            

  Male (*n* = 606)          308 (26.9%)        283 (21.9%)         15 (30%)           9.292         0.01

  Female (*n* = 1884)       837 (73.1%)        1012 (78.1%)        35 (70%)                         

  Age                                                                                               

  Average                   42.2 ± 11.89       44.2 ± 10.22        47.0 ± 12.93       14.1          \< 0.001

  Median                    42 (5--80)         45 (13--76)         47 (8--71)                       

  Weight                    64.8 ± 12.32       63.6 ± 10.35        62.9 ± 9.80        3.794         0.023

  Blood type                                                                                        

  A (*n* = 718)             312 (27.2%)        397 (30.7%)         9 (18.0%)          19.793        0.003

  B (*n* = 754)             325 (28.4%)        408 (31.5%)         21 (42.0%)                       

  AB (*n* = 382)            184 (16.1%)        186 (14.4%)         12 (24.0%)                       

  O (*n* = 636)             324 (28.3%)        304 (23.5%)         8 (16.0%)                        

  Lesion                                                                                            

  Unilateral (*n* = 1473)   683 (59.7%)        752 (58.1%)         38 (76.0%)         6.62          0.037

  Bilateral (*n* = 1017)    462 (40.3%)        543 (41.9%)         12 (24.0%)                       

  Focal                                                                                             

  Unifocal (*n* = 1370)     714 (62.4%)        625 (48.3%)         31 (62.0%)         20.596        \<0.001

  Multifocal (*n* = 1120)   488 (42.6%)        670 (51.7%)         19 (38.0%)                       

  LN metastasis                                                                                     

  Yes (*n* = 1174)          826 (72.1%)        984 (76.0%)         12 (24.0%)         67.426        \< 0.001

  No (*n* = 1316)           319 (27.9%)        311 (24.0%)         38 (76.0%)                       

  *BRAF* mutation\                                                                                  
  (*n* = 1708)                                                                                      

  Yes (*n* = 1444)          644/761 (84.6%)    792/928 (85.3%)     8/19 (42.1%)       36.646        \< 0.001

  No (*n* = 264)            117/761 (15.4%)    136/928 (14.7%)     11/19 (57.9%)                    

  Recurrence                                                                                        

  Yes                       90 (7.9%)          94 (7.3%)           4 (8.0%)           0.330         0.848

  No                        1055 (92.1%)       1201 (92.7%)        46 (92.0%)                       
  ------------------------------------------------------------------------------------------------------------

LN, lymph node.

Correlation between *BRAF* status and clinical features {#tca12858-sec-0015}
-------------------------------------------------------

More than 80% of patients had *BRAF* ^V600E^ mutations, but these occurred more often in women than in men. To investigate the relationship between clinicopathological features and *BRAF* ^V600E^ expression, all patients were divided into *BRAF* ^V600E^ positive and negative groups. As shown [5](#tca12858-tbl-0005){ref-type="table"}, there were significant differences in age (*P* = 0.019), lesions (*P* \< 0.001), focal status (*P* = 0.001), histological type (*P* \< 0.001), and lymph nodes (*P* \< 0.001) between patients with or without *BRAF* ^V600E^ mutations. Multiple logistic analyses showed that age (odds ratio \[OR\] 0.957, 95% confidence interval \[CI\] 0.944--0.970; *P* \< 0.001), focal status (OR 16.174, 95% CI 9.257--28.262; *P* \< 0.001), pathology (OR 0.642, 95% CI 0.473--0.871; *P* = 0.004), and lymph node metastasis (OR 0.059, 95% CI 0.033--0.107; *P* \< 0.001) were independent factors for *BRAF* ^V600E^ mutation.

###### 

Correlation between *BRAF* status and clinical features

  ----------------------------------------------------------------------------------------
  Index                      *BRAF* positive\   *BRAF* negative\   *χ* ^2^/*F*     *P*
                               (*n* = 1444)       (*n* = 264)                   
  ------------------------- ------------------ ------------------ ------------- ----------
  Gender                                                                        

  Male (*n* = 418)                 351                 67             0.139        0.71

  Female (*n* = 1290)              1093               197                       

  Age                                                                           

  Average                      44.1 ± 10.76       39.4 ± 11.60        5.547       0.019

  Median                       44 (14--80)         39 (6--69)                   

  Lesion                                                                        

  Unilateral (*n* = 1389)          1153               236            13.392      \< 0.001

  Bilateral (*n* = 319)            291                 28                       

  Focal                                                                         

  Unifocal (*n* = 919)             753                166            10.343       0.001

  Multifocal (*n* = 789)           691                 98                       

  Histological type                                                             

  PTC (*n* = 725)                  605                120             35.7       \< 0.001

  PTMC (*n* = 952)                 827                125                       

  FTC (*n* = 13)                    5                  8                        

  MTC (*n* = 1)                     0                  1                        

  Others (*n* = 7)                  4                  3                        

  LN metastasis                                                                 

  Yes (*n* = 1059)             943 (65.3%)        116 (43.9%)        43.245      \< 0.001

  No (*n* = 649)                   501                148                       
  ----------------------------------------------------------------------------------------

FTC, follicular thyroid cancer; LN, lymph node; MTC, medullary thyroid cancer; PTC, papillary thyroid cancer; PTMC, papillary thyroid microcarcinoma.

Discussion {#tca12858-sec-0016}
==========

The incidence of thyroid cancer has been steadily increasing in recent years and several studies have identified gender or racial/ethnic differences in incidence, clinicopathologic variables, gene expression, and prognosis.[9](#tca12858-bib-0009){ref-type="ref"}, [10](#tca12858-bib-0010){ref-type="ref"}, [11](#tca12858-bib-0011){ref-type="ref"} In 2013, Rose *et al*. reported regional differences in thyroid cancer presentation and survival rates, but not within separate racial/ethnic groups.[12](#tca12858-bib-0012){ref-type="ref"} We investigated the features of thyroid cancer in northwest China. Consistent with the results of previous reports, we found a higher incidence of thyroid cancer in women, at a ratio of 3:1. A vast majority of patients in our sample were diagnosed with PTC, while other types, primarily FTC or MTC, accounted for only 2% of cases; contrary to our result, previous studies have indicated an incidence rate in other types of 5%.[13](#tca12858-bib-0013){ref-type="ref"}, [14](#tca12858-bib-0014){ref-type="ref"} Although FTC and MTC are more aggressive types, they are associated with a lower rate of lymph node recurrence. Distant metastasis was the main cause of death and the most common locations were the lungs and bones in both our study sample and in previous reports.[15](#tca12858-bib-0015){ref-type="ref"}, [16](#tca12858-bib-0016){ref-type="ref"}

Cancer of the thyroid gland in pediatric patients is a rare and more aggressive disease.[17](#tca12858-bib-0017){ref-type="ref"} Patients aged ≤ 20 years account for 2.75% of all patients with thyroid cancer, but unfortunately the incidence appears to be increasing.[18](#tca12858-bib-0018){ref-type="ref"}, [19](#tca12858-bib-0019){ref-type="ref"} In this study, 2.6% (65/2490) of thyroid cancer patients were aged \< 21. The low incidence and limited availability of prospective randomized trials means that there is currently a lack of evidence‐based understanding of thyroid cancer in children. In 2009, Hogan *et al*. reported that in 1753 cases in children, 83% were PTC, 10% were FTC, 5% MTC, and 2% were other types.[20](#tca12858-bib-0020){ref-type="ref"} In our sample, PTC and PTMC accounted for 90.7% of all younger patients; 7.7% and 1.5% had FTC and MTC, respectively. The same guidelines for the treatment of adult patients are used to treat children with thyroid neoplasia, but these may not be appropriate.[21](#tca12858-bib-0021){ref-type="ref"} When choosing a treatment regimen, pediatric patients undergo total or near‐total thyroidectomy, considering the child\'s growth and the need for a second operation. Repeated radioactive iodine therapy or re‐operation in cases of recurrence are reported to have negative effects on children\'s development. Prophylactic lymph node dissection is also debated and is not currently recommended for children.[22](#tca12858-bib-0022){ref-type="ref"} RAI ablation with 131I is often used after surgery to detect metastatic disease, treat residual tumors and metastases, and to ablate any remaining normal thyroid tissue to allow more accurate monitoring for recurrent disease.[23](#tca12858-bib-0023){ref-type="ref"} In our patient sample, 83.1% of children were treated with RAI ablation. However, the ideal adjuvant treatment for children with thyroid cancer following primary surgery is unclear. Moreover, it is important to note that attention should be paid to the psychological health of children with cancer. If necessary, regular psychological intervention should be considered.

*BRAF* mutations are correlated with more aggressive and iodine‐resistant phenotypes and represent the most common oncogenic event in thyroid cancer, providing valuable prognostic information.[24](#tca12858-bib-0024){ref-type="ref"} *BRAF* mutations are associated with other clinicopathological parameters, which may prove to be predictive biomarkers of therapeutic response; however, more studies are needed to confirm the viability of these potential biomarkers.[25](#tca12858-bib-0025){ref-type="ref"} In 2012, Kurtulmus *et al*. reported a *BRAF* ^V600E^ mutation rate of 39.45% in thyroid cancer patients.[26](#tca12858-bib-0026){ref-type="ref"} In 2013, Fernandez *et al*. reported that *BRAF* ^V600E^ mutations occurred in 77.4% of classic PTC patients, 31.9% of the follicular variant, and 72.2% of high tall cell PTCs.[27](#tca12858-bib-0027){ref-type="ref"} In our sample, 84.5% of patients had *BRAF* ^V600E^ mutations: 84.6% in classic PTCs, 85.3% in PTMCs, and 42.1% in the other types. These mutations were associated with age, multicentricity, histologic subtype, and lymph node metastasis. In 2013, Lim *et al*. demonstrated that *BRAF* ^V600E^ mutations were significantly associated with large tumor size, extrathyroidal extension, and lymph node metastasis.[28](#tca12858-bib-0028){ref-type="ref"} In contrast, Ming *et al*. found no significant association between *BRAF* ^V600E^ mutations and gender, tumor size, histological subtype, multifocality, or accompanying nodular goiter and Hashimoto\'s; however, in thyroid cancer patients \< 21 years, the *BRAF* ^V600E^ mutation rate was 53.3%, approximately 30% lower than in older patients.[29](#tca12858-bib-0029){ref-type="ref"} By contrast, Henke *et al*. observed *BRAF* ^V600E^ mutations in 63% of pediatric thyroid cancer patients, which occurred more often in male than in female patients.[30](#tca12858-bib-0030){ref-type="ref"} Thus, the clinical significance of *BRAF* ^V600E^ gene mutation in thyroid cancer is unresolved and more evidence is needed to establish guidelines.

The overall prognosis of thyroid cancer patients, particularly those with differentiated thyroid cancer, is excellent. Factors associated with recurrent thyroid cancer include extrathyroidal extension of the primary tumor, bulky nodal metastatic lesions, macroscopic local invasion, and aggressive histologic subtypes.[31](#tca12858-bib-0031){ref-type="ref"} In this study, the recurrence rates of participants in various age groups were similar at approximately 8%, except for pediatric thyroid cancer patients who had a relatively higher probability of recurrence. In 2014, Mehanna *et al*. reported a recurrence rate in PTMC patients of 7.9%.[32](#tca12858-bib-0032){ref-type="ref"} In 2015, Joo *et al*. reported a 7.4% regional lymph node recurrence rate in PTC patients.[33](#tca12858-bib-0033){ref-type="ref"} Meanwhile, Pedrazzini *et al*. suggested that total or near‐total thyroidectomy might reduce the risk of local recurrences in non‐incidental PTMC, while prophylactic dissection of central compartment nodes in the absence of clinically evident metastases did not seem to change the risk of recurrence.[34](#tca12858-bib-0034){ref-type="ref"} Moreover, RAI ablation of thyroid remnants should only be considered in young patients with multifocal tumors and histologically proven metastatic lymph nodes with a significantly higher risk of recurrence.[34](#tca12858-bib-0034){ref-type="ref"}

In conclusion, this retrospective study revealed the real world clinicopathological features, treatment, and prognosis of thyroid cancer from a single medical center located in northwest China. Most of our results are similar to reported data, such as the higher incidence of disease in women and the larger proportion of patients with PTC. However, there is insufficient evidence to conclude which factors are associated with prognosis in pediatric patients and in patients with *BRAF* gene mutations.

Disclosure {#tca12858-sec-0018}
==========

No authors report any conflict of interest.

This work was funded by the National Science Foundation of China (No. 81572917).

[^1]: These authors contributed equally to this work.
